FDA issues warnings over compounded GLP-1s in telehealth, highlighting regulatory gaps in biotech innovation
Original framing: “STAT+: FDA warns more telehealth firms about compounded GLP-1s” — STAT News
Scientific studies on compounded GLP-1s are limited, and their long-term safety and efficacy have not been rigorously evaluated in large clinical trials. This lack of data complicates regulatory decisions and highlights the need for more research into the pharmacokinetics and variability of compounded formulations.
The FDA's warnings about compounded GLP-1s in telehealth highlight a systemic gap between rapid biotech innovation and outdated regulatory frameworks.
This issue is compounded by the exclusion of Indigenous and traditional knowledge systems, which offer alternative models for personalized and holistic health. Historically, compounded medications have served as a bridge to access in underserved communities, yet they remain in a legal gray area that limits their potential. Scientific evidence on the safety and efficacy of compounded GLP-1s is limited, and the voices of marginalized patients are often absent from policy discussions. To move forward, a multi-dimensional approach is needed—one that integrates scientific rigor, cross-cultural perspectives, and patient-centered innovation. This could involve developing new regulatory pathways, expanding access to affordable alternatives, and incorporating traditional knowledge into health policy. By addressing these dimensions together, the U.S. healthcare system can better balance innovation with safety and equity.